HM-107(HM-107) - 药物靶点：Neuropeptide S receptor family_专利_临床

概要

基本信息

药物类型

小分子化药

别名

neuropeptide S analog (HolsboerMaschmeyer)、HM-107

靶点

Neuropeptide S receptor family

作用机制

神经肽S受体家族调节剂

治疗领域

其他疾病

在研适应症-

非在研适应症

焦虑症

原研机构

Hmnc Diagnostics Gmbh

在研机构-

非在研机构

Hmnc Diagnostics Gmbh

最高研发阶段无进展药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 HM-107 相关的临床结果

登录后查看更多信息

100 项与 HM-107 相关的转化医学

登录后查看更多信息

100 项与 HM-107 相关的专利（医药）

登录后查看更多信息

28

项与 HM-107 相关的文献（医药）

2023-12-01·Neuropharmacology

RTI-263, a biased neuropeptide S receptor agonist that retains an anxiolytic effect, attenuates cocaine-seeking behavior in rats

Article

作者: Reissner, Kathryn J ; Ettaro, Robert ; Huang, Yuanli ; Runyon, Scott P ; Carvalho Costa, Paula ; DiStasio, Jacob ; Wojciechowski, Alaina ; Veros, Kaliana ; Feldman, Kyle ; Peirick, Jennifer J ; Ritter, Morgan ; Clark, Stewart D

Neuropeptide S (NPS) is a neuromodulatory peptide that acts via a G protein-coupled receptor. Centrally administered NPS suppresses anxiety-like behaviors in rodents while producing a paradoxical increase in arousal. In addition, NPS increases drug-seeking behavior when administered during cue-induced reinstatement. Conversely, an NPS receptor (NPSR) antagonist, RTI-118, decreases cocaine-seeking behavior. A biased NPSR ligand, RTI-263, produces anxiolytic-like effects and has memory-enhancing effects similar to those of NPS but without the increase in arousal. In the present study, we show that RTI-263 decreased cocaine seeking by both male and female rats during cue-induced reinstatement. However, RTI-263 did not modulate the animals' behaviors during natural reward paradigms, such as palatable food intake, feeding during a fasting state, and cue-induced reinstatement of sucrose seeking. Therefore, NPSR biased agonists are a potential pharmacotherapy for substance use disorder because of the combined benefits of decreased drug seeking and the suppression of anxiety.

2023-01-01·Pest management science

Insecticidal efficacy and risk assessment of different neuropeptide analog combinations against the peach‐potato aphid following topical exposure

Article

作者: Smagghe, Guy ; Nachman, Ronald J ; Shi, Yan ; Liu, Tong‐Xian ; Li, Hao

Abstract:

Background:

Insect neuropeptides control essential physiological metabolic activities. In our previous studies, Capability/CAP2b (PK/CAPA) analog 1895 applied alone or as a combination of CAPA analogs (1895 + 2315) was reported to decrease aphid fitness. While this was obtained with the combination of two peptide analogs of the same neuropeptide class, the effect of combining peptide analogs of different neuropeptide classes has not been explored so far.

Results:

In this study, we assessed the effect of combinations of the PK/CAPA analog 1895 with neuropeptide analogs of four different classes [adipokinetic hormone (AKH) analog: 2271; myosuppressin analog: 2434; kinin analog: 2460; tachykinin‐related peptide analog: 2463] on the fitness of aphids. We found that the combination of 1895 and AKH analog 2271 was the most effective one to control Myzus persicae. The triple combination 1895 + 2271 + 2315 provided a synergistic effect by further increasing aphid mortality and reducing reproduction relative to 1895 + 2315. Additionally, a biosafety assessment of the combination 1895 + 2271 + 2315 showed no significant lethal nor sub‐lethal effects on survival rates and food intake for the pollinator (Bombus terrestris) and the two representative natural enemies (Harmonia axyridis and Nasonia vitripennis).

Conclusion:

These results could facilitate establishment of the triple combination 1895 + 2271 + 2315, and/or inclusion of second generation analogs, as alternatives to broad spectrum and less friendly insecticides. © 2022 Society of Chemical Industry.

2021-08-03·The International journal of neuroscience4区 · 医学

The effect of chronic neuropeptide-S treatment on non-motor parameters in experimental model of Parkinson’s disease

4区 · 医学

Article

作者: Agar, Aysel ; Aslan, Mutay Aydın ; Ozkan, Ayse ; Akcay, Guven ; Bülbül, Mehmet ; Derin, Narin ; Sinen, Osman

AIM:

Besides motor impairment, non-motor symptoms including cognitive decline, anxiety, and depression are observed in Parkinson's Disease (PD). The aim of this study was to investigate whether chronic administration of central neuropeptide-S (NPS) improves non-motor symptoms in 6-hydroxydopamine (6-OHDA)-induced parkinsonian rats.

MATERIAL AND METHODS:

Experimental PD was utilized by unilateral stereotaxic injection of the 6-OHDA into the medial forebrain bundle (MFB), while the sham-operated animals underwent the same surgical procedures. NPS (1 nmol) or vehicle was daily administered through an intracerebroventricular (icv) cannula for 7 days. Radial arm maze (RAM) test was used to evaluate the working memory; whereas, elevated plus maze (EPM) test and sucrose preference test were used to monitor the anxiety and depression status, respectively. The levels of dopamine, glutamic acid, and glutamine was determined in harvested striatal and hippocampal tissue samples. The immunoreactivities for tyrosine hydroxylase (TH) was determined using immunohistochemistry.

RESULTS:

In the RAM test, the 6-OHDA-induced increases in the reference and working memory errors were reduced by the central NPS administration. The decreased sucrose preference in the parkinsonian rats was increased by centrally administered NPS. The levels of dopamine levels in striatum and hippocampus were decreased in the parkinsonian rats, however, they were not altered by the centrally administered NPS. Additionally, NPS treatment significantly attenuated the 6-OHDA-induced loss of TH neuronal number.

CONCLUSION:

Consequently, NPS appears to be a therapeutic candidate for the treatment of non-motor complications of PD.

100 项与 HM-107 相关的药物交易

登录后查看更多信息